Measuring change in inclusion body myositis: clinical assessments versus imaging.
Clin Exp Rheumatol
; 40(2): 404-413, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-35225227
ABSTRACT
Sporadic inclusion body myositis (sIBM) is a heterogeneous progressive inflammatory muscle disease impacting skeletal muscles in the head, neck, and limbs. Use of valid, reliable, sensitive, and standardised clinical and paraclinical outcome assessments (COA) are critical to inform both proactive clinical care and clinical trial design. Here we review clinical and imaging methods used to quantify muscle strength, size, or function in sIBM, and discuss their application to clinical practice and use in clinical trials. Considerations for future work to validate measures in this population are also discussed.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myositis, Inclusion Body
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Clin Exp Rheumatol
Year:
2022
Document type:
Article
Affiliation country:
Estados Unidos